UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

Annals of oncology, 2018-10, Vol.29 (10), p.2052-2060

2018

Volltextzugriff (PDF)

Cetuximab-related skin toxicity and efficacy: do we understand the mechanisms?

Annals of oncology, 2020-07, Vol.31 (7), p.964-965

2020

Volltextzugriff (PDF)

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial

Annals of oncology, 2024-10, Vol.35 (10), p.873-881

2024

Volltextzugriff (PDF)

Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma

Annals of oncology, 2024-09, Vol.35 (9), p.780-791

2024

Volltextzugriff (PDF)

Iron deficiency during first-line chemotherapy in metastatic cancers: a prospective epidemiological study

Supportive care in cancer, 2020-04, Vol.28 (4), p.1639-1647

2020

Volltextzugriff (PDF)

A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)

ESMO open, 2022-08, Vol.7 (4), p.100529-100529, Article 100529

2022

Volltextzugriff (PDF)

Regorafenib combined with irinotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas: A randomized phase 2 trial (PRODIGE 58 – UCGI 35 – REGIRI)

Annals of oncology, 2019-07, Vol.30, p.iv21-iv21

2019

Volltextzugriff (PDF)

Stereotactic Pelvic Reirradiation for Locoregional Cancer Relapse

Clinical oncology (Royal College of Radiologists (Great Britain)), 2021-01, Vol.33 (1), p.e15-e21

2021

Volltextzugriff (PDF)

Nécrose digitale sous pembrolizumab : un évènement thrombotique rare

La revue de medecine interne, 2018-06, Vol.39, p.A198-A199

2018

Volltextzugriff (PDF)

EP-1267: Induction chemotherapy followed by chemoradiotherapy in locally advanced pancreatic adenocarcinoma

Radiotherapy and oncology, 2016-04, Vol.119, p.S597-S597

2016

Volltextzugriff (PDF)

‘Folfirinox’ chemotherapy combined with contact x-ray brachytherapy 50 kVp and ‘CAP50’ chemoradiotherapy aiming at organ preservation for selected intermediate distal-middle cT2-T3 rectal cancers: A feasibility study

Cancer radiothérapie, 2024-08, Vol.28 (4), p.323-332

2024

Volltextzugriff (PDF)

397MO Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in HER2-negative advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma (GC/GEJC): PD-L1 biomarker analysis from RATIONALE-305

Annals of oncology, 2024-06, Vol.35, p.S160-S161

2024

Volltextzugriff (PDF)

517P Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: The RASINTRO prospective multicenter study

Annals of oncology, 2024-09, Vol.35, p.S438-S438

2024

Volltextzugriff (PDF)

102P Potentially prognostic factors of overall survival in advanced biliary tract cancer in the randomised phase III TOPAZ-1 study

Annals of oncology, 2023-10, Vol.34, p.S220-S220

2023

Volltextzugriff (PDF)

SO-8 Predictive values of blood-based RNA signature for the FOLFIRINOX/FOLFOX response in advanced pancreatic cancer

Annals of oncology, 2023-06, Vol.34, p.S164-S165

2023

Volltextzugriff (PDF)

Placement of metallic biliary endoprostheses in complex hilar tumours

Diagnostic and interventional imaging, 2012-10, Vol.93 (10), p.767-774

2012

Volltextzugriff (PDF)

Mise en place d’endoprothèses biliaires métalliques dans les tumeurs hilaires complexes

Journal de radiologie diagnostique et interventionnelle, 2012-10, Vol.93 (10), p.814-821

2012

Volltextzugriff (PDF)

562P Acquired genomic alterations on first-line chemotherapy (CT) + cetuximab in advanced colorectal cancer (mCRC): Circulating tumor (ct)DNA analysis of the randomized phase II trial TIME-PRODIGE-28

Annals of oncology, 2024-09, Vol.35, p.S461-S461

2024

Volltextzugriff (PDF)

Geriatric Assessment in older patients with pancreatic adenocarcinoma

Journal of geriatric oncology, 2023-11, Vol.14 (8), p.S37

2023

Volltextzugriff (PDF)

LBA2 POD1UM-303/InterAACT 2: Phase III study of retifanlimab with carboplatin-paclitaxel (c-p) in patients (Pts) with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) not previously treated with systemic chemotherapy (Chemo)

Annals of oncology, 2024-09, Vol.35, p.S1217-S1217

2024

Volltextzugriff (PDF)

504O IMHOTEP Phase II trial of neoadjuvant pembrolizumab in dMMR/MSI tumors: Results of the colorectal cancer cohort

Annals of oncology, 2024-09, Vol.35, p.S429-S429

2024

Volltextzugriff (PDF)

1448P IMHOTEP phase II trial of neoadjuvant pembrolizumab in dMMR/MSI localized cancers: Results of the digestive non-colorectal cancer cohorts

Annals of oncology, 2024-09, Vol.35, p.S899-S900

2024

Volltextzugriff (PDF)

1204MO PRODIGE 59 - DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma

Annals of oncology, 2022-09, Vol.33, p.S1099-S1100

2022

Volltextzugriff (PDF)

LBA23 Avelumab versus standard second-line treatment chemotherapy in metastatic colorectal cancer (mCRC) patients with microsatellite instability (MSI): The SAMCO-PRODIGE 54 randomised phase II trial

Annals of oncology, 2022-09, Vol.33, p.S1390-S1391

2022

Volltextzugriff (PDF)

1 – 25 von 110

Suche als RSS-Feed

Aktive Filter

PublikationsformReviews

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(84)
Mit Volltextzugriff
(102)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(70)
Französisch
(40)

Erscheinungsjahr

n.n

Thema

Science & Technology
(26)
Physical Sciences
(14)
Physics
(14)
Life Sciences & Biomedicine
(12)
Exact Sciences And Technology
(10)
Oncology
(10)
Aged
(7)
Female
(7)
Humans
(7)
Male
(7)
Technology
(7)
Bolometers
(6)
Engineering
(6)
France
(6)
Histoire De La Littérature
(6)
Histoire Et Sciences De La Litterature
(6)
Littératures Francophones
(6)
Littératures Francophones Et Anglophones
(6)
Middle Aged
(6)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300

Cetuximab-related skin toxicity and efficacy: do we understand the mechanisms?

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial

Development and validation of AI-assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma

Iron deficiency during first-line chemotherapy in metastatic cancers: a prospective epidemiological study

A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)

Regorafenib combined with irinotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas: A randomized phase 2 trial (PRODIGE 58 – UCGI 35 – REGIRI)

Stereotactic Pelvic Reirradiation for Locoregional Cancer Relapse

Nécrose digitale sous pembrolizumab : un évènement thrombotique rare

EP-1267: Induction chemotherapy followed by chemoradiotherapy in locally advanced pancreatic adenocarcinoma

‘Folfirinox’ chemotherapy combined with contact x-ray brachytherapy 50 kVp and ‘CAP50’ chemoradiotherapy aiming at organ preservation for selected intermediate distal-middle cT2-T3 rectal cancers: A feasibility study

397MO Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in HER2-negative advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma (GC/GEJC): PD-L1 biomarker analysis from RATIONALE-305

517P Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: The RASINTRO prospective multicenter study

102P Potentially prognostic factors of overall survival in advanced biliary tract cancer in the randomised phase III TOPAZ-1 study

SO-8 Predictive values of blood-based RNA signature for the FOLFIRINOX/FOLFOX response in advanced pancreatic cancer

Placement of metallic biliary endoprostheses in complex hilar tumours

Mise en place d’endoprothèses biliaires métalliques dans les tumeurs hilaires complexes

562P Acquired genomic alterations on first-line chemotherapy (CT) + cetuximab in advanced colorectal cancer (mCRC): Circulating tumor (ct)DNA analysis of the randomized phase II trial TIME-PRODIGE-28

Geriatric Assessment in older patients with pancreatic adenocarcinoma

LBA2 POD1UM-303/InterAACT 2: Phase III study of retifanlimab with carboplatin-paclitaxel (c-p) in patients (Pts) with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) not previously treated with systemic chemotherapy (Chemo)

504O IMHOTEP Phase II trial of neoadjuvant pembrolizumab in dMMR/MSI tumors: Results of the colorectal cancer cohort

1448P IMHOTEP phase II trial of neoadjuvant pembrolizumab in dMMR/MSI localized cancers: Results of the digestive non-colorectal cancer cohorts

1204MO PRODIGE 59 - DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma

496TiP Randomised phase II study evaluating trifluridine/tipiracil (FTD/TPI) plus oxaliplatin ± nivolumab versus FOLFOX ± nivolumab in patients with HER2-negative locally advanced, recurrent or metastatic gastric, oesophageal or junctional adenocarcinoma (aGA/GEJA) (PRODIGE 73 - LOGICAN)

LBA23 Avelumab versus standard second-line treatment chemotherapy in metastatic colorectal cancer (mCRC) patients with microsatellite instability (MSI): The SAMCO-PRODIGE 54 randomised phase II trial

Aktive Filter

Suchergebnisse filtern